In current practice, Next Generation Sequencing (NGS) applications start with mapping/aligning short reads to the reference genome, with the aim of identifying genetic mutations. While most short reads can be mapped to the reference genome accurately by existing alignment tools, a significant number remain unmapped and excluded from downstream analyses thus potentially discarding important biological information hidden in the unmapped reads. This paper describes Genesis-indel, a computational pipeline that explores the unmapped reads to identify novel indels that are initially missed in the alignment procedure. Genesis-indel is applied to the unmapped reads of 30 Breast Cancer patients from TCGA. Results show that the unmapped reads are conserved between the two subtypes of breast cancer investigated in this study and might contribute to the divergence between the subtypes. Genesis-indel is able to leverage the unmapped reads to identify 72,997 small to large novel high-quality indels previously not found in the original alignments and among them, 16,141 have not been annotated in the widely used mutation database. Statistical analysis shows that these new indels mostly altered the oncogenes and tumor suppressor genes.
Introduction
Next Generation Sequencing (NGS) facilitates generation of an enormous number of short reads and allows the identification of genomic mutations that cause phenotype changes and genetic diseases such as Mendelian disorders [1] , Acute Myeloid Leukemia [2] , and Lung cancer [3] .
Applications analyzing the NGS reads typically start with mapping the short reads against a reference genome and then based on the mapped reads, determine the genetic mutations such as Single Nucleotide Polymorphism (SNP) and sequence variants such as Insertion and Deletion (indel) of bases. Many alignment algorithms have been developed to map the short reads to the reference genome such as MAQ [4] , SOAP [5] , BWA [6] , Bowtie [7] , Bowtie2 [8] , SNAP [9] , and SOAP2 [10] , to name a few. Although these alignment tools are very efficient in aligning the short reads, a nonnegligible fraction of reads are left unmapped due to (1) structural variants longer than the allowed number of gaps and mismatches by the mapper, (2) sequencing error, or (3) sample contamination [11] . In current practice, these unmapped reads are not used for variant calling and downstream analyses, and thus mutations harbored in these unmapped reads remain hidden from any inference on important genotype and phenotype and/or their associations with any disease such as cancer. However, as shown in Figure 1 , some of the "hidden" or "missing" mutations can contain the key for understanding the molecular mechanisms of genetic diseases or cancer and might be used as markers for disease/cancer diagnosis and prognosis. The consequence of missing the mutations contained in the unmapped reads can lead to inaccurate downstream analyses such as characterizing the tumor evolution in a cancer patient. Some of these missed mutations can be the hallmark of tumors and can be useful for targeted therapy. Therefore, it is critical to identify the mutations in those regions for clinical decision-making as well as for guided personal treatment [12, 13] . With this objective in mind, it is essential to inspect the unmapped reads previously excluded from analyses to ensure that none of these essential mutations are missed in those regions of interest.
This paper describes Genesis-indel, a computational pipeline to explore unmapped reads for the systematic identification of indels missed in the original alignments. Note that this pipeline focuses on indels only, the second most abundant form of genetic variation in human populations [14] [15] [16] .
Despite being a common form of genetic variation in humans, indels have not been studied as thoroughly as SNPs, though they have been identified playing a key role in causing diseases such as Cystic fibrosis [17] , Fragile X Syndrome [18] , acute myeloid leukemia [2, 19, 20] , and lung cancer [21] . In addition, insertion of transposable elements such as Alu can affect gene function and change gene expression [22] . Genesis-indel is applied to explore unmapped reads of 30 breast cancer patients from The Cancer Genome Atlas (TCGA) [23] and identify indels hidden in the unmapped reads of these patient genomes. Results show that unmapped reads can be used to cluster samples to different cancer subtypes. In addition, Genesis-indel can successfully curate the unmapped reads and detect small to large novel high-quality indels that are missed previously and some of these indels are specific to a particular subtype of breast cancer. Functional annotation of the newly identified indels shows that the indels found from unmapped reads are strongly correlated with cancer pathways and may play an important role in cancer progression. In addition, these indels overlap with genes where no mutation was found from the original alignments and these genes can contribute to the tumorigenesis in multiple cancers. Therefore, this study shows great promise in complementing the current procedure of understanding the underlying mechanism of cancer progression and will be useful for clinical decision making.
Figure 2:
Genesis-indel workflow. The input to Genesis-indel is the alignment file (BAM file) and the reference genome (FASTA format). First, the unmapped reads are extracted from the input BAM and passed to the quality control module. After quality control, the reads are mapped to the reference genome using BWA-MEM. The reads that still remained unmapped are aligned using BLAT. In the merging step, the output of BWA-MEM and BLAT are merged and duplicates are marked using Picard. The merged alignment is then passed to the Variant Calling module followed by quality filtering of the indels. Finally, the output contains novel high-quality indels rescued from the originally unmapped reads. Figure 2 shows the schematic of the Genesis-indel workflow (see Methods for detail). Genesisindel is used to identify the novel high-quality indels from the alignment (BAM files) of 30 Breast Cancer patients deposited in TCGA. These BAM files were originally produced by mapping the raw sequencing reads of these patients to the human reference genome using BWA [6] .
Results and Discussion

Existence of a nonnegligible number of originally unmapped reads
The alignment file of each patient sample is processed by using SAMtools [24] to extract the "Originally Unmapped" reads. For a given individual investigated here, 6.6 to 74 million reads are unmapped (average = 31.86 million). Shown in Figure 3 , the unmapped reads constitute an average of 5% of the total reads (altogether there are more than 955 million reads unmapped for 30 patient samples) in the original alignment files provided by TCGA. Genesis-indel targets these discarded reads to rescue the indels missed in the original alignment. 
Quality control of the unmapped reads
Since it is likely that the unmapped reads might be of low quality and hence ignored by the mapper, the extracted unmapped reads are processed for quality control. The unmapped reads from all samples are combined and passed to FastQC [25] to get various statistics of the reads. According to the report produced by FastQC, the originally unmapped reads have some quality issues such as (1) overall poor per base sequence quality, (2) a poor score for per sequence quality, (3) overrepresentation of "N" contents, (4) overrepresentation of Illumina Paired-End PCR Primer 2 due to PCR over-amplification, and (5) other adapter contents ( Supplementary Figures 1(a) , 2(a), and 3(a)). In most cases, reads that are contaminated with adapter sequences are simply not mapped because of sequencing errors in the adapter sequences. Therefore, removing these contaminated sequences is expected to improve the quality of the unmapped reads. Trimmomatic [26] is applied to the combined unmapped reads from all samples and then FastQC is used again to assess the quality of the reads. As shown in Supplementary Figures 1(b) , 2(b), and 3(b), after trimming adapter sequences, many issues were fixed and the quality of the unmapped reads improved significantly. Although there is a low-quality issue with some k-mer noise at the 3' end of the reads ( Supplementary Figure 4) , the mapping is not affected by these k-mers as they are not mapped to the reference genome and hence get discarded during the alignment step. Alternatively, RAUR (Re-align the Unmapped Reads) [27] could be used for read quality control. RAUR analyzes the base quality distribution of sequencing error and adopts an iterative trimming algorithm to remove a segment of low-quality bases from the unmapped read so that the remaining segment of the originally unmapped read can be confidently mapped. After combining RAUR with alignment tools such as BWA and Bowtie2, the alignment rate is improved as observed by Peng et al. [27] .
However, RAUR is not publicly available and hence could not be considered for Genesis-indel pipeline. After the quality control by Trimmomatic, for the individuals investigated here, 29.29% to 89.5% of the originally unmapped reads are retained (average = 67.68%) constituting around 647 million reads.
Mapping the quality controlled unmapped reads
After quality control, the unmapped reads are mapped to the reference genome using BWA-MEM [28] . BWA-MEM can automatically choose between local and end-to-end alignments. It is applicable to map short as well as long reads, and is sensitive in mapping reads with indels. While mapping, unlike other short-read mappers, it allows big gaps potentially caused by structural variants and shows better or comparable performance than several state-of-the-art read mappers to date in terms of speed and accuracy [28] . This mapper is robust to sequencing errors as well. After the reads are aligned by BWA-MEM, some reads still remain unmapped. At this step, another local alignment tool, BLAT (BLAST-Like Alignment Tool) [29] is used to align these reads. After this step, the alignments from BWA-MEM and BLAT are merged. Counting the number of newly mapped reads reveal that 65.38% of the originally unmapped reads (624,892,089 out of 955,822,913) now get mapped to the reference genome. Out of these newly mapped reads, BWA-MEM mapped 479,064,451 reads and BLAT aligned 145,827,638 reads. As mentioned before, the mapper used by TCGA is BWA and although theoretically, BWA can map arbitrarily long reads, practically, the performance in mapping long reads degraded with the increase of the sequencing error rate [27] . By removing the bases with sequencing error and using BWA-MEM which is a robust and variant sensitive mapper coupled with another sensitive aligner BLAT, Genesis-indel manages to map many of the initially unmapped reads. Figure 4 shows the average mapping quality of the newly mapped reads for all samples. For most of the samples, the mapping quality is higher than that of the originally mapped reads (Supplementary Figure 5 ). 
Identifying the novel high-quality indels from the newly mapped reads
Genesis-indel uses Platypus [30] to call indels from the newly mapped reads. Separately, indels are also called from the reads that are originally mapped. Platypus is chosen as it performed the best among other existing indel callers based on real data as reported in a recent review [31] . After variant calling, indels from the newly mapped reads are inspected for any match with the indels found in the originally mapped reads. As shown in Figure 5 , an indel already in the originally mapped reads can be called again in the newly mapped reads. Since the main objective is to identify novel indels from the originally unmapped reads, these re-identified indels (3.58% of the total number of indels identified from the originally mapped reads) are discarded from the downstream analysis. This step produces 105,331 novel insertions and 143,386 novel deletions from the newly mapped reads. These indels are referred to as "Novel indels" in this paper. Figure 5 : An example of an insertion that is already in the originally mapped reads can be called again in the newly mapped reads. Since this indel can be found in the originally mapped reads and hence not novel by definition, this indel is discarded in the downstream analysis.
Examination of the flags of the novel indels shows that for many of the indels, Platypus does not produce a high confidence value. Therefore, to consider only the high-quality indels for further analysis, novel indels are filtered again to make sure that only high-quality indels are reported finally. Therefore, only novel indels with "PASS" flags are considered for the final result and are termed as "Novel high-quality indel" in this paper. These novel high-quality indels are the ones for which the indel caller has high confidence. In total, Genesis-indel reports 31,924 novel highquality insertions (43.73% of the total novel high-quality indels) and 41,073 novel high-quality deletions (56.27% of the total novel high-quality indels) from the 30 samples investigated here.
The deletion to insertion ratio for the novel high-quality indel is 1.29:1, close to the deletion to insertion ratio for originally mapped reads which is 1.11: 1 (7,313,641 insertions and 8,082,055 deletions). Although this paper focuses on indels only, as shown in Figure 6 , in addition to indels, new SNPs are also identified by Genesis-indel in the originally unmapped reads. 
Frameshift indels are more frequent than in-frame types in the novel high-quality indels
Novel high-quality indels identified here contain 53,623 frameshift and 19,374 in-frame indels, indicating a higher abundance of the frameshift indels in the unmapped reads. Frameshift indels are also found more abundant than in-frame indels in the originally mapped reads (13,911,266 vs 1,481,550). Frameshift mutations are common in cancer patients and increase the susceptibility to cancers and other diseases by causing loss of significant fractions of proteins [33] [34] [35] [36] which indicates the significance of these newly identified frameshift indels. Frameshift indels of longer length (≥15 bases) are more frequent than in-frame indels of corresponding length (585 insertions, 1,479 deletions vs. 404 insertions, 812 deletions).
Mills et al. studied the landscape of small indels in the genomes of 79 healthy humans and found that 53.5 and 46.5% of these indels are frameshift and in-frame indels, respectively [37] . However, in a study by Iengar et al. [36] on COSMIC indels, it is found that 75.7% and 24.3% of the indels are frameshift and in-frame indels, respectively, which means unlike the distribution of coding indels in the genome of healthy people, frameshift indels are preferred over in-frame indels in cancer genome. Therefore, in addition to the frameshift indels from the originally mapped reads, the novel high-quality frameshift indels uncovered by Genesis-indel may harbor important signals for further analysis.
Novel high-quality indels have more diverse length than indels in the originally mapped reads Figure 7 shows the distribution of the length of the novel high-quality indels analyzed here. It is observed that insertion and deletion frequency decreases with the increase in the size of the insertion and deletion. The longest novel high-quality insertion and deletion are 28 and 45 bases, respectively (34 and 55 bases for the indels from the originally mapped reads). It is expected that the novel indels would be long as they might have been missed because the lengths might exceed the number of gaps and mismatches allowed by the mapper. Surprisingly, as shown in Figure 7 , most of the newly discovered indels (91% of insertion and 88.1% of deletion) are short indels (≤10 bases) indicating the limitation of the mapper used in the TCGA project. A paired two-tailed t-test shows that the indel length distribution of novel high-quality indels is significantly different from that of indels identified from the originally mapped reads (p-value = 0.00025). Newly mapped reads can add more support to indels not recognized in the originally mapped reads Most variant calling programs rely on hard evidence for indels marked in the alignment and therefore require a minimum number of reads to support an indel. This step is required to distinguish real variants from the artifacts of sequencing errors. As shown in Figure 8 
Clustering of the samples based on quality-controlled unmapped reads
The samples are compared pairwise using the quality controlled unmapped reads in order to identify biologically relevant signals and to cluster the samples based on the number of similar reads. Pairwise distance is calculated for the unmapped reads from each sample using Mash, a distance estimator based on MinHash [38] . This pairwise distance is then used to cluster the samples. Figure 9 shows the hierarchical clustering of the samples based on Mash distance. The clustering results are then compared with the samples' PAM50 subtypes collected from TCGA [39] . Out of the total 30 samples, 16 belong to the Basal subtype and the remaining 14 belong to LumA. As shown in figure 9, all but three samples (samples 12, 13, and 14) cluster with the samples of their respective subtype. These three samples belong to Basal subtype but clustered with the samples from LumA subtype. The result reveals that the unmapped reads are most commonly shared among the samples of the same subtype and suggests that these unmapped reads might contribute to the divergence between the two subtypes investigated here. This result also implies that perhaps there is a subtype-specific common cause of mapping failure. These results indicate that the sets of unmapped reads contain sequence information specific to sample subtype and hence leveraging such information may help understand or interpret the related biological questions. This suggests possible subtype mislabeling of these samples.
Novel high-quality indels are checked to see if they are specific to any of the two subtypes (Basal and LumA) investigated here. An indel is defined as specific to a subtype when it is found in the samples of one subtype and not in the samples of the other subtype. After checking all of the novel high-quality indels, it is found that 89 of the indels are specific to Basal subtype and no such indels are found from the samples investigated here for the LumA subtype.
Novel high-quality indels overlapped with the oncogenes and tumor suppressor genes
To see which oncogenes and tumor suppressor genes are frequently affected by the newly discovered indels, a list consisting of 142 protein-coding genes (79 oncogenes and 63 tumor suppressor genes) (see Methods) is overlapped with the novel high-quality indels using BEDtools [40] . In total, 62 out of these 142 genes overlapped with these indels. Among these 62 genes, 32 are oncogenes and the remaining ones are tumor suppressor genes. Table 1 lists the top ten genes with the number of indels identified in these genes. The highest number of indels (54) are identified in RUNX1 (Runt Related Transcription Factor 1), a protein-coding tumor suppressor gene. A gene with that many unique indels definitely contains the important signature of breast cancer. Although RUNX1 has received attention as a gene fusion in acute myeloid leukemia (AML) [41, 42] , a putative link to breast cancer has recently emerged [43] . However, this gene has not gained enough attention and hence its role in breast cancer remains elusive [44] . One reason for the understudy of the RUNX1 gene is the underpowered expression profile studies as identified by Janes et al. [45] . Another reason, as the result shows here, could be because of not discovering the indels hidden in the unmapped reads. Therefore this study is complementary to the study performed by Janes et al. [45] . Table 1 : Top ten oncogene and tumor suppressor genes and the number of indels identified in these genes.
Gene
Number of Indel Frameshift indels are more abundant than in-frame indels in both oncogenes and tumor suppressor genes. Some genes contain only in-frame indel and some contain only frameshift indels. As shown in Table 2 , out of the 62 genes overlapped with the novel high-quality indels, 46 contain either inframe or frameshift indels. The remaining 16 genes contain both in-frame and frameshift indels.
As shown in the previous section, frameshift indels are the dominant type of indels and RUNX1 contains the maximum number of indels for both in-frame (12) and frameshift (42) among all genes investigated here, making it an important gene in breast cancer progression. 
Indel Type Gene
In-frame Oncogenes (5) 
Novel high-quality indels mostly alter cancer-related genes than noncancer-related genes
A list of whole genome protein-coding genes not containing the oncogene and tumor suppressor gene is generated from the whole genome gene list produced by GENCODE (version 28 lift37).
This list contains 20,172 genes and among these, 6,829 genes are found overlapped with the novel high-quality indels. A hypothesis testing is done to compare the proportion of novel high-quality indels appearing in cancer-related genes (oncogene and tumor suppressor gene) to that in noncancer genes. Statistically, the hypothesis being tested is as follows,
where 1 denotes the proportion of oncogenes and tumor suppressor genes that overlapped with the novel high-quality indels, i.e., 62/142 = 0.44 and 2 denotes the proportion of noncancer genes that overlapped with the novel high-quality indels, i.e., 6829/20172 = 0.34.
To test this hypothesis, the standard normal test statistic, z is calculated as follows.
Considering the tail area, α = 0.05, the critical point for this right-tailed test is 0.05 = 1.64. Based on these data and using the formula (1), the observed value of z is 2.35. Since the value of z exceeds the critical point of 1.64, the null hypothesis, 0 : 1 ≤ 2 can be rejected at the α = 0.05 (p-value = 0.009386706). Therefore, the proportion of cancer genes overlapping with novel high-quality
indels is significantly higher than the proportion for noncancer genes.
A permutation test can also be done to see if the novel high-quality indels have a higher enrichment in cancer genes (oncogenes and tumor suppressor genes) than in noncancer genes. For this test, from the list containing 20,172 genes (the whole genome gene list not containing the oncogene and tumor suppressor genes), 142 genes (number of total oncogene and tumor suppressor genes) are sampled randomly and repeatedly. The bootstrapping is done 1,000 times yielding 1,000 sets containing 142 genes each. Figure 10 : Probability density plot for 1,000 sets containing randomly selected 142 genes overlapped with the novel high-quality indels. The black dot on the right tail represents the value for 62, the number of cancer genes (oncogenes and tumor suppressor genes) overlapped with the novel high-quality indels.
To test the hypothesis, each of these 1,000 sets of randomly picked 142 genes is overlapped with the novel high-quality indels to yield a null distribution of the number of overlaps. Figure 10 shows the probability density plot of such overlap count for 1,000 repetitions. As determined in the previous section, the number of cancer genes (oncogenes and tumor suppressor genes) overlapped with novel high-quality indel is 62. Therefore, the probability density for the number of overlap > 62 (right tail of the density plot) in these random set of indels is calculated as the p-value of the one-sided permutation test. Only in 9 out of 1,000 sets, the number of overlap is higher than 62 and therefore, the p-value is 9/1000 = 0.009 (which is also consistent with the p-value from the ztest above) and since it is < 0.05, the null hypothesis can be rejected. Therefore, it can be concluded that the enrichment of the novel high-quality indels in cancer genes is significantly higher than that in noncancer genes.
Annotating the novel high-quality indels using Variant Effect Predictor (VEP)
For this analysis, the novel high-quality indels are annotated using Variant Effect Predictor (VEP) [46] . 16 ,141 of the indels are identified as novel, i.e., not annotated in the Ensembl variation database consisting of dbSNP, Cancer Gene Census, ClinVar, COSMIC, dbGap, DGVa etc. This indicates the significance of this study in rescuing these novel high-quality indels from the discarded reads that can potentially be annotated.
The combined list of indels overlapped with 15,229 genes, 32,335 transcripts, and 2,136 regulatory features. As shown in Figure 11 (a), around 75% of the novel high-quality indels are in the noncoding regions located in the intron or intergenic region. Figure 11 by influencing chromatin modification, mRNA splicing, and protein translation [47, 48] as well as contribute to mammary tumor development [49, 50] and progression. Therefore the novel highquality indels overlapped with these transcripts deserve more attention and studying these indels has biological significance. 
Functional annotation of the overlapping genes
Functional annotation of the genes overlapping with the novel high-quality indels using David [51] (version 6.7) shows strong correlation with "Pathways in Cancer" (Fisher Exact p-value: 6.2 × 10 −5 ), "PI3K-Akt signaling pathway" (Fisher Exact p-value: 1.5 × 10 −4 ), RAP1 signaling pathway (Fisher Exact p-value: 10 −4 ), and RAS signaling pathway (Fisher Exact p-value: 4.7 × altered in cancers and the survival signals induced by several receptors are mediated mainly by this pathway [52] . Ras-associated protein-1 (RAP1) is an important regulator of cell functions and has been found playing a vital role in cell invasion and metastasis in cancers [53] . The signaling pathways involving RAS protein can contribute to tumor growth, survival, and spread, and play a crucial role in the pathogenesis of other hematologic malignancies as well [54, 55] . Therefore, these results suggest that the newly found indels interacting with these genes may participate in cancer-related biological processes and play an important role in cancer progression.
Genes missed in the original mapping but found in novel high-quality indels show association with cancer and other diseases
There are 42 genes overlapping with the novel high-quality indels but not with the indels from the originally mapped reads. Table 3 lists the genes with their types. Functional annotation of the protein-coding genes using David shows that these genes are related to biological process such as immune response, protein localization, protein transport, regulation of transcription, and regulation of RNA metabolic process which can control molecular functions such as antigen binding, peptide binding, MHC protein binding, and peptide-antigen binding. In addition, these genes are associated with protein domain such as Immunoglobulin subtype and Krueppel-Associated Box (KRAB)-Zinc Finger Protein (ZFP). Immunoglobulin subtype is involved in cell-cell recognition, cellsurface receptors, muscle structure, and the immune system [56] and therapy targeting this protein domain has been used for liver cancer [57] , breast cancer [58] , and Follicular Lymphoma [59, 60] .
Krueppel-Associated Box (KRAB)-Zinc Finger Protein (ZFP) is the largest class of transcription factors in the human genome [61] and is largely involved in tumorigenesis [62] . Table 3 : Name and type of the genes that overlap with the novel high-quality indels but with the indels from the originally mapped reads.
Gene Type Gene Name
Antisense RP11-534L20.5, JMJD1C-AS1, CTB-22K21. A PubMed search returned results for three genes namely KIF20A, BNIP3P1, and ZNF84.
Kinesin family member 20A (KIF20A), also known as RAB6KIFL, is a member of the kinesin superfamily of motor proteins, a conserved motor domain which binds to microtubules to generate the energy required for trafficking of proteins and organelles during the growth of numerous cancers [63, 64] . KIF20A is found overexpressed at both the mRNA and protein levels than the normal counterparts in breast cancer [65] [66] [67] and also in several other cancers including gastric cancer [68] , bladder cancer [69, 70] , pancreatic cancer [71] [72] [73] , hepatocellular cancer [74] , lung cancer [75] , glioma [76] , and melanoma [77] . The overexpression of KIF20A gene is significantly associated with the poor survival of breast cancer patient [65, 66] and drug resistance [66, 78] .
Similar phenomena are observed with other cancer patients as well [68, 70, 71, 73, 75, 79] .
Silencing or knockdown of KIF20A can significantly inhibit cell proliferation and cancer progression [72, 80] . Therefore, KIF20A has been suggested as a direct therapeutic target [72, 81] and KIF20A-derived peptide has been used in immunotherapy in clinical trials to improve the prognosis of cancer patients [63, 76, [82] [83] [84] [85] . Although KIF20A has a strong association with breast cancer, no mutation is found in this gene from the originally mapped reads which shows the limitation of the current approach and this limitation can be alleviated by exploring the unmapped resulted in a cardiomyopathy phenotype. A similar congenital restrictive cardiomyopathy is also identified to be caused by the deletion resulting in loss-of-function of KIF20A [86] . Despite such significance, these two variants that affect protein function were absent in the population control exome such as ExAC Browser database, a catalog of genetic data of 60,706 humans of various ethnicities [87] . The missense variant was found in two individuals from South Asia and Europe and the frameshift deletion was present in 32 individuals of African descent [86, 88] . This observation supports the claim that clinically important mutations can be missed and one of the reasons might be because of overlooking the unmapped reads. By exploring the unmapped read of 30 breast cancer patients, Genesis-indel finds a frameshift deletion of T (chr5:137520225 CT -> C) that overlaps with the exon of KIF20A gene ( Figure 12 ). Among the remaining genes, BCL2 interacting protein 3 pseudogene 1 (BNIP3P1) is found to be upregulated in patients with Breast Cancer Brain Metastases when compared to Breast Cancer (76% vs. 24%) or compared to Primary Brain Tumors (74% vs. 26%) [89] and is suggested to be used as a molecular biomarker for Breast Cancer Brain Metastases. Zinc Finger Protein 84 (ZNF84) is found significantly associated with tumor size and TNM (Tumor, Node, Metastases) staging for cervical cancer and squamous cell carcinoma and in vitro validation shows that it promotes cell proliferation via AKT signaling pathway [90] . Although the literature doesn't show any association between these genes and breast cancer, it is worth exploring due to their association with other cancers.
Out of the 42 genes, two LincRNAs namely RP3-416J7.4 and RP11-386I8.6 contain the same number of indels as the protein-coding genes. Although little is known about their association with breast cancer, analysis using TANRIC [91] on TCGA-BRCA data reveals that these two LincRNAs are differentially expressed (t-test p-value = 0.000023337 and 0.003812, respectively) between the carriers and non-carriers of somatic mutations in the TP53 gene, a tumor suppressor gene spontaneously found altered in breast carcinomas [92] .
While this paper shows the significance of uncovering novel high-quality indels from the originally unmapped reads in patients with breast cancer, there are a couple of limitations. Firstly, this study is conducted by using a computational pipeline. Though the pipeline is computationally feasible and results are convincing as well as supported by experimentally validated literature, it lacks some validation experiments in vivo to govern the clinical importance of the newly identified indels.
Secondly, filtering indels solely based on the "PASS" flag may cause missing rare variants.
Therefore, an algorithm such as ForestQC [93] which combines traditional variant filtering approach with machine learning algorithm to determine the quality of the variant can be incorporated to the present pipeline to improve the quality control procedure and achieve better results.
Conclusion
This paper emphasizes the interest of the unmapped reads and the potential loss of important information and describes Genesis-indel, a computational pipeline to rescue novel high-quality indels by exploring unmapped reads that are normally discarded from the downstream analysis. to be subjected to further study. These novel high-quality indels are mainly enriched in frameshift indels and have high to moderate impact in the protein. These indels mostly alter the oncogenes and tumor suppressor genes and overlap with genes significantly related to different cancer pathways. Moreover, these indels overlap with genes not found in the indels from the originally mapped reads and functional annotation shows that these genes contribute to the development and growth of tumor in multiple carcinomas. Therefore, these findings collectively suggest that complete characterization of these indels is essential for downstream cancer research. Genesisindel is expected to be highly useful for uncovering the missed indels that can be further explored for clinical decision making.
Methods
The Genesis-indel pipeline
Genesis-indel is designed to leverage unmapped reads from an alignment with the goal to rescue indels that are hidden in the discarded unmapped reads. Figure 2 shows the schematic of the Genesis-indel workflow. The input to Genesis-indel is the alignment file (BAM file) of the patient genome and the reference genome. In the preprocessing step, Genesis-indel extracts the unmapped alignment by checking the alignment flag using SAMtools (version 1.4) [24] . From this, it extracts the "Originally Unmapped" reads using SAMtools and stores the reads in a FASTQ file. This These quality controlled single-end reads are used as input to the mapper in the next step.
The quality controlled unmapped reads are mapped to the reference genome using BWA-MEM (version 0.7.15-r1140) [28] , a sensitive mapper to map reads with indels. After the reads are aligned by BWA-MEM, some reads still remain unmapped. These reads are aligned to the reference genome using BLAT (BLAST-Like Alignment Tool) [29] , another sensitive local alignment tool. At the end of this step, the alignments from BWA-MEM and BLAT are merged.
The resultant alignment is sorted and indexed using SAMtools and duplicates are marked in the newly mapped reads using MarkDuplicates tool from Picard (version 1.65) [94] . After read alignment and duplicate removal, indels are called using Platypus (version 0.7.9.1). Separately, indels are also called from the original (input) BAM file. Indels found only in the newly mapped reads and not in the original alignment are reported as novel indels. After identifying the novel indels, another step of filtering is done to keep only the high-quality indels, i.e., the indels that are called with high confidence by Platypus. Therefore, only the indels with the "PASS" flags are reported at the final step. These are the novel high-quality indels reported in the final output and selected for downstream analysis.
Preparing a list of oncogene and tumor suppressor genes
A list of oncogenes and tumor suppressor genes is obtained from an online resource [95] , a list compiled from the CancerGenes [96] . 
